Biotech ETFs holding TGTX have outperformed NASDAQ benchmarks lately, which could indirectly lift the TGTX stock price due to passive investment inflows. RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30. TG Therapeutics reported second-quarter earnings per share of 17 cents, up from 4 cents a year ago, but below the consensus of 19 cents . Technical chart analysis shows TGTX stock price approaching a golden cross scenario, with the 50-day moving average nearing a cross above the 200-day—historically bullish.